{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:48:37Z","timestamp":1777394917500,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:p>Background: Many patients with Alzheimer\u2019s disease and related dementia (ADRD) have chronic hepatitis C due to the high prevalence of both conditions among elderly populations. Direct-acting antivirals (DAAs) are effective in treating hepatitis C virus (HCV). However, the complexity of ADRD care may affect DAA use and outcomes among patients with HCV and ADRD. Little information exists on uptake of DAAs, factors associated with DAA use, and health benefits of DAAs among patients with HCV and ADRD. Objective: To examine use and survival benefits of DAAs in Medicare patients with HCV and ADRD. Methods: The study included Medicare patients with HCV between 2014 and 2017. We estimated Cox proportional hazards regressions to examine the association between having ADRD and DAA use, and the relation between DAA use and survival among patients with HCV and ADRD. Results: The adjusted hazard of initiating a DAA was 50% lower in patients with ADRD than those without ADRD (adjusted HR\u200a=\u200a0.50, 95% CI: 0.46\u20130.54). The hazard of DAA use among ADRD patients with behavioral disturbances was 68% lower than non-ADRD patients (adjusted HR\u200a=\u200a0.32, 95% CI: 0.28\u20130.37). DAA treatment was associated with a significant reduction in mortality among ADRD patients (adjusted HR\u200a=\u200a0.52, 95% CI: 0.44\u20130.61). Conclusion: The rate of DAA treatment in patients with HCV and ADRD was low, particularly among those with behavioral disturbance. The survival benefits of DAA treatment for patients with ADRD were substantial.<\/jats:p>","DOI":"10.3233\/jad-200949","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:35:35Z","timestamp":1605616535000},"page":"71-83","source":"Crossref","is-referenced-by-count":5,"title":["Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C"],"prefix":"10.1177","volume":"79","author":[{"given":"Linh","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Health Policy and Administration, College of Health and Human Development, Pennsylvania, State University, University Park, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeah","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Administration, College of Health and Human Development, Pennsylvania, State University, University Park, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Carlin","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, School of Medicine, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Medicine, University of California, Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA"},{"name":"Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Feldman","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Management, School of Public Health, University of Minnesota, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200949_ref1","doi-asserted-by":"crossref","unstructured":"(2020) 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 16, 391\u2013460.","DOI":"10.1002\/alz.12068"},{"key":"10.3233\/JAD-200949_ref3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2020.02.022","article-title":"Receipt of eye care services among medicare beneficiaries with and without dementia","volume":"127","author":"Pershing","year":"2020","journal-title":"Ophthalmology"},{"key":"10.3233\/JAD-200949_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0192-4","article-title":"Comorbidity and dementia: A scoping review of the literature","volume":"12","author":"Bunn","year":"2014","journal-title":"BMC Med"},{"key":"10.3233\/JAD-200949_ref5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.0306-5251.2001.01401.x","article-title":"Drug therapy in the elderly: What doctors believe and patients actually do","volume":"51","author":"Barat","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JAD-200949_ref6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1067\/mcp.2001.119812","article-title":"Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study","volume":"70","author":"Salas","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JAD-200949_ref7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1532-5415.2012.03907.x","article-title":"Receipt of monitoring of diabetes mellitus in older adults with comorbid dementia","volume":"60","author":"Thorpe","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-200949_ref8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-181292","article-title":"Differences in cataract surgery rates based on dementia status","volume":"69","author":"Pershing","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200949_ref9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1532-5415.2004.52461.x","article-title":"Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia","volume":"52","author":"Gupta","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-200949_ref10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/WNL.0b013e31823648f1","article-title":"Care and outcomes in patients with ischemic stroke with and without preexisting dementia","volume":"77","author":"Saposnik","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-200949_ref11","doi-asserted-by":"crossref","first-page":"e14024","DOI":"10.1371\/journal.pone.0014024","article-title":"Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: A cohort study","volume":"5","author":"Vitry","year":"2010","journal-title":"PLoS One"},{"key":"10.3233\/JAD-200949_ref12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1464-5491.2009.02872.x","article-title":"Co-morbidity and the utilization of health care for Australian veterans with diabetes","volume":"27","author":"Zhang","year":"2010","journal-title":"Diabet Med"},{"key":"10.3233\/JAD-200949_ref13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"10.3233\/JAD-200949_ref15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/cid\/cis815","article-title":"Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study","volume":"56","author":"Moorman","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.3233\/JAD-200949_ref17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","article-title":"Hepatitis C virus as a systemic disease: Reaching beyond the liver","volume":"10","author":"Gill","year":"2016","journal-title":"Hepatol Int"},{"key":"10.3233\/JAD-200949_ref18","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"10.3233\/JAD-200949_ref19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"10.3233\/JAD-200949_ref20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-acting antiviral therapy for hepatitis c virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.3233\/JAD-200949_ref21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/14787210.2017.1354697","article-title":"Extrahepatic manifestations of HCV: The role of direct acting antivirals","volume":"15","author":"Polo","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.3233\/JAD-200949_ref22","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-019-53051-2","article-title":"Impact of direct acting antivirals on survival in patients with chronic hepatitis C and hepatocellular carcinoma","volume":"9","author":"Kamp","year":"2019","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200949_ref23","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of direct-acting antiviral treatment with mortality among medicare beneficiaries with hepatitis C","volume":"3","author":"Kalidindi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.3233\/JAD-200949_ref24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.3233\/JAD-200949_ref25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cgh.2014.01.025","article-title":"The end of hepatitis C","volume":"12","author":"Sussman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.3233\/JAD-200949_ref28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.sapharm.2015.11.011","article-title":"A scoping review on medication adherence in older patients with cognitive impairment or dementia","volume":"12","author":"Hudani","year":"2016","journal-title":"Res Social Adm Pharm"},{"key":"10.3233\/JAD-200949_ref29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/diseases6020051","article-title":"Adverse effects of direct acting antivirals in HIV\/HCV coinfected patients: A 4-year experience in Miami, Florida","volume":"6","author":"Gonzales Zamora","year":"2018","journal-title":"Diseases"},{"key":"10.3233\/JAD-200949_ref30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4140\/TCP.n.2004.713","article-title":"Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors","volume":"19","author":"Hughes","year":"2004","journal-title":"Consult Pharm"},{"key":"10.3233\/JAD-200949_ref33","first-page":"1236","article-title":"Racial\/ethnic and socioeconomic disparities in use of direct-acting antivirals among medicare beneficiaries with chronic hepatitis C, 2014\u20132016","volume":"25","author":"Jung","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.3233\/JAD-200949_ref34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-017-0405-6","article-title":"Statistical methods for elimination of guarantee-time bias in cohort studies: A simulation study","volume":"17","author":"Cho","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.3233\/JAD-200949_ref35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: Immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"key":"10.3233\/JAD-200949_ref36","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural history and management of hepatitis C: Does sex play a role?","volume":"209","author":"Baden","year":"2014","journal-title":"J Infect Dis"},{"key":"10.3233\/JAD-200949_ref37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/ijerph16060934","article-title":"Adverse drug events in patients with dementia and neuropsychiatric\/behavioral, and psychological symptoms, a one-year prospective study","volume":"16","author":"Hernandez","year":"2019","journal-title":"Int J Environ Res Public Health"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:32Z","timestamp":1777370672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":30,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-200949","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}